RNA Interference-Mediated Silencing of the Polo-like Kinase 1 Gene Enhances Chemosensitivity to Gemcitabine in Pancreatic Adenocarcinoma Cells Export

@article{citeulike:2605010, abstract = {ABSTRACT Gemcitabine is the first-line chemotherapeutic agent for advanced adenocarcinoma of the pancreas; however, chemoresistance to gemcitabine remains a major cause of failure for the clinical treatment of this disease. Polo-like kinase 1 (Plk-1) is highly expressed in pancreatic cancer cell lines and pancreatic tumor tissues, and is involved in a wide variety of cell cycle processes. Nevertheless, its biological role and implication for gemcitabine resistance are not clearly defined. In this study, we used RNA-interference (RNAi)-mediated depletion of Plk-1 to determine its potential for sensitizing pancreatic tumor cells to gemcitabine. We showed that the level of Plk-1 protein was correlated significantly with gemcitabine resistance in human pancreatic adenocarcinoma cells and that overexpression of Plk-1 reduced sensitivity to gemcitabine in these cells. In addition, small interfering RNA (siRNA)-mediated knockdown of Plk-1 caused cell cycle arrest at G2/M and the reduction of cellular proliferation. More importantly, the treatment of pancreatic cancer cells with Plk-1 siRNA followed by exposure to gemcitabine dramatically decreased cell viability and increased cellular apoptosis, as compared with treatment with either agent alone. These observations indicate that down-regulation of Plk-1 expression by RNAi enhances gemcitabine sensitivity and increases gemcitabine cytotoxicity in pancreatic tumor cells. This is the first demonstration that the combination of Plk-1 gene therapy and gemcitabine chemotherapy has synergistic anti-tumor activity against pancreatic carcinoma in vitro. This combination treatment warrants further investigation as an effective therapeutic regimen for patients with resistant pancreatic cancer and other tumors.}, author = {Chunzhao, Y. U. and Zhang, Xinhua and Gu, S. U. N. and Xirong, G. U. O. and Huabing, L. I. and Yongping, Y. O. U. and Gardner, Kevin and Depei, Y. U. A. N. and Zekuan, X. U. and Qing, D. U. and Cengcai, D. A. I. and Zhuyin, Q. I. A. N. and Jiang, Kuirong and Yi, Z. H. U. and Jacobs, Jonathan L. and Li, Qingdi Q. and Yi, M. I. A. O.}, citeulike-article-id = {2605010}, citeulike-linkout-0 = {http://www.blackwell-synergy.com/doi/abs/10.1111/j.1582-4934.2008.00257.x}, citeulike-linkout-1 = {http://dx.doi.org/10.1111/j.1582-4934.2008.00257.x}, doi = {10.1111/j.1582-4934.2008.00257.x}, journal = {Journal of Cellular and Molecular Medicine}, keywords = {apoptosis, biology, cancer, genes, protein, rna, rnai}, number = {ja}, posted-at = {2008-03-28 05:16:42}, priority = {0}, title = {RNA Interference-Mediated Silencing of the Polo-like Kinase 1 Gene Enhances Chemosensitivity to Gemcitabine in Pancreatic Adenocarcinoma Cells}, url = {http://dx.doi.org/10.1111/j.1582-4934.2008.00257.x}, volume = {0}, year = {0} }

TY - JOUR ID - citeulike:2605010 L3 - citeulike-article-id:2605010 N2 - ABSTRACT Gemcitabine is the first-line chemotherapeutic agent for advanced adenocarcinoma of the pancreas; however, chemoresistance to gemcitabine remains a major cause of failure for the clinical treatment of this disease. Polo-like kinase 1 (Plk-1) is highly expressed in pancreatic cancer cell lines and pancreatic tumor tissues, and is involved in a wide variety of cell cycle processes. Nevertheless, its biological role and implication for gemcitabine resistance are not clearly defined. In this study, we used RNA-interference (RNAi)-mediated depletion of Plk-1 to determine its potential for sensitizing pancreatic tumor cells to gemcitabine. We showed that the level of Plk-1 protein was correlated significantly with gemcitabine resistance in human pancreatic adenocarcinoma cells and that overexpression of Plk-1 reduced sensitivity to gemcitabine in these cells. In addition, small interfering RNA (siRNA)-mediated knockdown of Plk-1 caused cell cycle arrest at G2/M and the reduction of cellular proliferation. More importantly, the treatment of pancreatic cancer cells with Plk-1 siRNA followed by exposure to gemcitabine dramatically decreased cell viability and increased cellular apoptosis, as compared with treatment with either agent alone. These observations indicate that down-regulation of Plk-1 expression by RNAi enhances gemcitabine sensitivity and increases gemcitabine cytotoxicity in pancreatic tumor cells. This is the first demonstration that the combination of Plk-1 gene therapy and gemcitabine chemotherapy has synergistic anti-tumor activity against pancreatic carcinoma in vitro. This combination treatment warrants further investigation as an effective therapeutic regimen for patients with resistant pancreatic cancer and other tumors. IS - ja JF - Journal of Cellular and Molecular Medicine TI - RNA Interference-Mediated Silencing of the Polo-like Kinase 1 Gene Enhances Chemosensitivity to Gemcitabine in Pancreatic Adenocarcinoma Cells VL - 0 KW - apoptosis KW - biology KW - cancer KW - genes KW - protein KW - rna KW - rnai AU - Chunzhao, YU AU - Zhang, Xinhua AU - Gu, SUN AU - Xirong, GUO AU - Huabing, LI AU - Yongping, YOU AU - Gardner, Kevin AU - Depei, YUAN AU - Zekuan, XU AU - Qing, DU AU - Cengcai, DAI AU - Zhuyin, QIAN AU - Jiang, Kuirong AU - Yi, ZHU AU - Jacobs, Jonathan AU - Li, Qingdi AU - Yi, MIAO PY - 2000/// UR - http://dx.doi.org/10.1111/j.1582-4934.2008.00257.x ER -